您当前的位置：
首页 >
文章列表页 >
Rapid health technology assessment of lecanemab in the treatment of early-stage Alzheimer’s disease
更新时间：2026-02-27

    • Rapid health technology assessment of lecanemab in the treatment of early-stage Alzheimer’s disease

    • “The latest research focuses on the treatment of early Alzheimer's disease, evaluating the effectiveness, safety, and cost-effectiveness of lencanavir monoclonal antibody. Research has found that the drug can significantly delay cognitive decline, but there is a high risk of ARIA and economic burden.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 4, Pages: 504-509(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.04.16    

      CLC： R972;R965

    • Received：16 September 2025，

      Revised：2026-02-02，

      Accepted：05 February 2026，

      Published：28 February 2026

    移动端阅览

  • SHA Pian,WANG Xiaojie,WANG Tao.Rapid health technology assessment of lecanemab in the treatment of early-stage Alzheimer’s disease[J].ZHONGGUO YAOFANG,2026,37(04):504-509. DOI： 10.6039/j.issn.1001-0408.2026.04.16.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Cost-utility analysis of anlotinib combined with penpulimab in first-line treatment of unresectable hepatocellular carcinoma
Rapid health technology assessment of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis
Denosumab in the Treatment of Giant Cell Tumor of Bone ：A Health Technology Assessment

Related Author

YAN Wenying
YANG Na
ZHANG Ranran
TAO Xinyue
GAO Shengnan
LIU Guoqiang
GAO Xing
KONG Shujing

Related Institution

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital
Hebei Provincial Society for Integrated Drug and Health Technology Assessment
Dept. of Dermatology， the Affiliated Hospital of Xuzhou Medical University
Dept. of Anesthesiology， the Affiliated Hospital of Xuzhou Medical University
0